Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The New Microbiologica

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 25938744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterisation of Trabecular Bone Structure

  2013cited by this paper
• Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy

  2013cited by this paper
• Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting

  2013cited by this paper
• Stable bone mineral density over 6 years in HIV‐infected men treated with highly active antiretroviral therapy (HAART)

  2012cited by this paper
• Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis

  2011cited by this paper
• Stable bone density in HAART-treated individuals with HIV: a meta-analysis.

  2011cited by this paper
• Improvement in Vitamin D Deficiency Following Antiretroviral Regime Change: Results from the MONET Trial

  2011cited by this paper
• Prospective study of bone mineral density changes in aging men with or at risk for HIV infection

  2010cited by this paper
• High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study

  2010cited by this paper
• Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

  2010cited by this paper
• Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

  2009cited by this paper
• Continuous antiretroviral therapy decreases bone mineral density

  2009cited by this paper
• Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

  2009cited by this paper
• Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.

  2009cited by this paper
• Bone loss in patients with HIV infection.

  2009cited by this paper
• Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation

  2008cited by this paper
• Effect of Lopinavir/Ritonavir Monotherapy on Quality of Life and Self-Reported Symptoms among Antiretroviral-Naive Patients: Results of the MONARK Trial

  2008cited by this paper
• Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

  2006cited by this paper
• Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection

  2005cited by this paper
• Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches.

  2005cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

  2004cited by this paper
• Relationship Between Low Bone Mineral Density and Highly Active Antiretroviral Therapy Including Protease Inhibitors in HIV-Infected Patients

  2003cited by this paper
• Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy

  2003cited by this paper
• HIV Infection—A Risk Factor for Osteoporosis

  2003cited by this paper
• HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D

  2003cited by this paper
• Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

  2001cited by this paper
• Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report

  1994cited by this paper
• On aging bone loss.

  1982cited by this paper

• Advancements in development of novel class of HIV protease inhibitors

  2026cites this paper
• Impact of Alcohol on Bone Health in People Living With HIV: Integrating Clinical Data From Serum Bone Markers With Morphometric Analysis in a Non‐Human Primate Model

  2022cites this paper
• Impact of physical exercises on immune function, bone mineral density, and quality of life in people living with HIV/AIDS: a systematic review with meta-analysis

  2019cites this paper
• HIV and kidney: a dangerous liaison.

  2017cites this paper
• Risk factors in the HIV population Traditional CKD

  2017cites this paper
• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

  2016cites this paper
• Estudio metabólico y cardiovascular en una cohorte de pacientes infectados por el VIH-1: predisposición genética, aterosclerosis subclínica y eventos coronarios

  2015cites this paper
• Is monotherapy maintenance the way forward?

  2015cites this paper